Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN Vaccine Dose Reduction Strategies Trial
NCT05512949Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JYNNEOS in mpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2022; status: completed.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on NCT05512949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512949.